Renal denervation in the antihypertensive arsenal – knowns and known unknowns. Issue 10 (October 2022)

• Record Type: Journal Article
• Authors: Messerli, Franz H.; Bavishi, Chirag; Brguljan, Jana; Burnier, Michel; Dobner, Stephan; Elijovich, Fernando; Ferdinand, Keith C.; Kjeldsen, Sverre; Laffer, Cheryl L.; S Ram, C. Venkata; Rexhaj, Emrush; Ruilope, Luis M.; Shalaeva, Evgeniya V.; Siontis, George C.M.; Staessen, Jan A.; Textor, Stephen C.; Vongpatanasin, Wanpen; Vogt, Liffert; Volpe, Massimo; Wang, Jiguang; Williams, Bryan
• Is Part Of: Journal of hypertension. Volume 40:Issue 10(2022)
• Page Start: 1859
• Page End: 1875
• Publication Date: 2022-10
• Subjects: antihypertensive treatment -- blood pressure -- hypertension -- refractory hypertension -- renal denervation; Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000003171
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy has been made, it is still not clear how RDN fits into the antihypertensive arsenal. There is no question that RDN lowers blood pressure (BP), it does so to an extent at best corresponding to one antihypertensive drug. The procedure has an excellent safety record. However, it remains clinically impossible to predict whose BP responds to RDN and whose does not. Long-term efficacy data on BP reduction are still unconvincing despite the recent results in the SPYRAL HTN-ON MED trial; experimental studies indicate that reinnervation is occurring after RDN. Although BP is an acceptable surrogate endpoint, there is complete lack of outcome data with RDN. Clear indications for RDN are lacking although patients with resistant hypertension, those with documented increase in activity of the sympathetic system and perhaps those who desire to take fewest medication may be considered.